Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-25.00 | -0.83% | 2,975.00 | 2,900.00 | 3,050.00 | 3,000.00 | 2,975.00 | 3,000.00 | 2,717 | 14:56:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 13.61M | 8.1M | 1.5543 | 19.14 | 156.28M |
TIDMBVXP
RNS Number : 3901X
BioVentix PLC
25 April 2023
Bioventix plc
("Bioventix" or "the Company")
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 24 April 2023 that on 24 April 2023 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 11 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at an average price of 3,823 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment plan ("DRIP").
Following the Purchase, Bruce Hiscock has a beneficial interest in 761 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
Bioventix plc Tel: 01252 728 001 Peter Harrison Chief Executive Officer finnCap Ltd Tel: 020 7220 0500 Geoff Nash/Simon Hicks Corporate Finance Alice Lane ECM
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Bruce Hiscock ------------------------------- ---------------------------------- 2. Reason for the Notification ------------------------------------------------------------------- a) Position/status Chief Financial Officer ------------------------------- ---------------------------------- b) Initial notification/Amendment Initial notification ------------------------------- ---------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------- a) Name Bioventix Plc ------------------------------- ---------------------------------- b) LEI 213800225MHX7LZQY108 ------------------------------- ---------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------- a) Description of the Ordinary Shares of 5 pence each Financial instrument, type of instrument Identification code GB00B4QVDF07 ------------------------------- ---------------------------------- b) Nature of the transaction Purchase of Ordinary Shares ------------------------------- ---------------------------------- c) Price(s) and volume(s) 11 Ordinary Shares 3,823 pence ------------------------------- ---------------------------------- d) Aggregated information: Purchase of 11 Ordinary Shares at 3,823 pence each * Aggregated volume * Price ------------------------------- ---------------------------------- e) Date of the transaction 24 April 2023 ------------------------------- ---------------------------------- f) Place of the transaction London Stock Exchange, AIM Market (XLON) ------------------------------- ----------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEANLSADLDEEA
(END) Dow Jones Newswires
April 25, 2023 05:35 ET (09:35 GMT)
1 Year Bioventix Chart |
1 Month Bioventix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions